1The Consensus Trial Study Group. Effects of enalapril on mortality on severe congstive heart failure. N Engl J Med, 1987,316 : 1429-1435.
2The SOLVD Investigators. effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestion heart failure. N Engl J Med, 1991,325:293-302.
3Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med, 1991,325:303-310.
4Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure ( evaluation of losartan in the elderly study, ELITE ). Lancet, 1997,349:747-752.
5Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomized trial-the Losartan Heart Failure Survival Study ELITE Ⅱ. Lancet,2000,355 : 1582-1587.
6Cohn JN ,Tognoni G. A randomized trial of the agniotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001,345 : 1667-1675.
7Granger CB, McMurray JJ, Yusuf S, et al. , CHARM Investigators and Committees. Effects of candesattan in patints with chronic heart failure and reduced left-ventricular systolic function intolerant to angihensin convetting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003,362:772-776.
8McMurray JJ,Ostergren J, Swedberg K,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitors:the CHARM-Added trial.Lancet ,2003,372:767-771.
9Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial.Lancet ,2003,362:777-781.
10Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet,2003,362:759-766.
3Wong M, Staszewasky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study [ J ]. J Am Coll Cardiol, 2002, 40 (5) : 970 -975.
4McMurray JJ, Ostergren J, Swedberg K, et al. Effects of cande- sartan in patients with chronic heart failure and reduced left-ven- tricular systolic function taking' angiotensin converting enzyme in- hibitors: the CHARM-Added trial [ J]'. Lancet, 2003, 362 (9386) :767 -771.
5Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guide- line update for the diagnosis and management of chronic heart failure in the adult [ J]. Circulation, 2005, 112 ( 12 ) : 154 - 235.
6Athanasopoulos LV, Dritsas A, Doll HA, et al. Comparative value of NYHA functional class and quality of life questionnaire scores in assessing heart failure [ J ]. J Cardiopulm Rehabil Prev, 2010, 30(2) : 101 - 105.
7The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asympto-matic patients with reduced left ventricular ejection fractions [ J]. N Engl J Med, 1992, 327(10) : 685 -691.
8Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesar- tan in patients with chronic heart failure and reduced left-ven- tricular systolic function intolerant to angiotensin-converting-en- zyme inhibitors: the CHARM-Alternative trial[J]. The Lancet, 2003, 362(9386) :772 -776.
9陈珠.心功能不全[M].第11版.实用内科学,2001:1234-1255.
10Pang P,Konstam M,Krasa H. Effects of tolvaptan on dyspnoea relief from the EVEREST trials[J].{H}EUROPEAN HEART JOURNAL,2009.2233-2240.
